Patents by Inventor Jason M. PERRY

Jason M. PERRY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical compositions having improved storage stability
    Patent number: 11969469
    Abstract: The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent.
    Type: Grant
    Filed: August 10, 2021
    Date of Patent: April 30, 2024
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Jason M. Perry, Daniel R. Deaver, Magali B. Hickey, Julius F. Remenar, Jennifer Vandiver, Michael J. Palmieri, Jr., Zhengzheng Pan
  • PHARMACEUTICAL COMPOSITIONS COMPRISING SORBITAN ESTERS
    Publication number: 20240131024
    Abstract: The present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs.
    Type: Application
    Filed: October 31, 2023
    Publication date: April 25, 2024
    Inventors: Jason M. Perry, Daniel R. Deaver, Magali B. Hickey, Julius F. Remenar, Jennifer Vandiver
  • Pharmaceutical Compositions Comprising Sorbitan Esters
    Publication number: 20240058327
    Abstract: The present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs.
    Type: Application
    Filed: March 14, 2023
    Publication date: February 22, 2024
    Inventors: Jason M. PERRY, Daniel R. DEAVER, Magali B. HICKEY, Julius F. REMENAR, Jennifer VANDIVER
  • DIHYDROERGOTAMINE DRY POWDER FORMULATIONS AND METHODS OF USE
    Publication number: 20240033218
    Abstract: The present disclosure relates to dry powder formulations comprising respirable dry particles that comprise 1) dihydroergotamine (DHE) or a salt, hydrate, or polymorph thereof, 2) a monovalent metal cation salt, and 3) one or more excipients; and also relates to methods of using the dry powder for the treatment of a migraine, headache, or a symptom thereof, methods of making the dry powder, and receptacles and devices containing the dry powder.
    Type: Application
    Filed: March 1, 2022
    Publication date: February 1, 2024
    Inventors: Jason M. PERRY, Aidan K. CURRAN, Aaron C. GONZALEZ NELSON, Dayna F. HANSON, Hillary T. BERGSON, Eric C. STOLZ
  • Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
    Patent number: 11883394
    Abstract: Processes for providing depot injections of recrystallized aripiprazole lauroxil in which particles of the aripiprazole lauroxil have a surface area of about 0.50 to about 3.3 m2/g; and crystals of aripiprazole lauroxil produced by such processes.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: January 30, 2024
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Wilfredo Morales, Tarek A. Zeidan, Renato A. Chiarella, Steven G. Wright, Jason M. Perry
  • THREAT ANALYTICS AND DYNAMIC COMPLIANCE IN SECURITY POLICIES
    Publication number: 20240031411
    Abstract: This disclosure describes techniques and mechanisms for defining dynamic security compliance in networks to proactively prevent security policy violations from being added and/or made, retroactively and continuously identify security policy violations based on data from the changing threat landscape, and provide auto-remediation of non-compliant security policies. The techniques enable automated security policies and provide improved network security against a dynamic threat landscape.
    Type: Application
    Filed: July 22, 2022
    Publication date: January 25, 2024
    Inventors: Doron Levari, Tariq Ahmed Farhan, Vincent E. Parla, Ido Tamir, Adam Bragg, Jason M. Perry
  • Pharmaceutical Compositions Having Improved Storage Stability
    Publication number: 20220072133
    Abstract: The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent
    Type: Application
    Filed: August 10, 2021
    Publication date: March 10, 2022
    Inventors: Jason M. Perry, Daniel R. Deaver, Magali B. Hickey, Julius F. Remenar, Jennifer Vandiver, Michael J. Palmieri, JR., Zhengzheng Pan
  • Antifungal dry powders
    Patent number: 11116722
    Abstract: The invention relates to dry powder formulations comprising respirable dry particles that contain 1) an antifungal agent in crystalline particulate form, 2) a stabilizer, and 3) one or more excipients.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: September 14, 2021
    Assignee: Pulmatrix Operating Company, Inc.
    Inventors: Jason M. Perry, Jean C. Sung, David L. Hava, Robert Clifford Saunders, Hillary S. Bergson, Andrew Emmet O'Connor
  • Pharmaceutical compositions having improved storage stability
    Patent number: 11097006
    Abstract: The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: August 24, 2021
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Jason M. Perry, Daniel R. Deaver, Magali B. Hickey, Julius F. Remenar, Jennifer Vandiver, Michael J. Palmieri, Jr., Zhengzheng Pan
  • CRYSTALLIZATION PROCESS OF ARIPIPRAZOLE DERIVATIVES IN EXTENDED RELEASE FORMULATIONS FOR TREATMENT OF SCHIZOPHRENIA
    Publication number: 20210205302
    Abstract: Processes for providing depot injections of recrystallized aripiprazole lauroxil in which particles of the aripiprazole lauroxil have a surface area of about 0.50 to about 3.3 m2/g; and crystals of aripiprazole lauroxil produced by such processes.
    Type: Application
    Filed: March 24, 2021
    Publication date: July 8, 2021
    Inventors: Wilfredo Morales, Tarek A. Zeidan, Renato A. Chiarella, Steven G. Wright, Jason M. Perry
  • ANTIFUNGAL FORMULATIONS FOR PULMONARY ADMINISTRATION COMPRISING ITRACONAZOLE
    Publication number: 20210145739
    Abstract: The invention relates to dry powder formulations comprising respirable dry particles that contain 1) itraconazole in crystalline particulate form, 2) polysorbate 80, and 3) one or more excipients, wherein the ratio of itraconazole to polysorbate 80 (wt:wt) in the feedstock solution is greater than 10:1.
    Type: Application
    Filed: April 18, 2019
    Publication date: May 20, 2021
    Inventors: Jason M PERRY, David L HAVA, Robert C SAUNDERS, Andrew E O'CONNOR, Dayna HANSON
  • Methods of Treating Fungal Infections
    Publication number: 20210113461
    Abstract: The invention relates to methods of treating fungal infections by administering to the respiratory tract of a patient in need thereof an effective amount of an anti-fungal agent, preferably itraconazole, wherein said anti-fungal agent is administered in an amount sufficient to concurrently achieve a) a lung concentration of anti-fungal agent of at least 500 ng/g or ng/mL and b) a plasma concentration of anti-fungal agent of no more than 25 ng/mL. The preferred form is as dry powder inhalation.
    Type: Application
    Filed: April 18, 2019
    Publication date: April 22, 2021
    Inventors: Jason M. PERRY, David L. HAVA, Aidan CURRAN
  • Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
    Patent number: 10973816
    Abstract: Processes for providing depot injections of recrystallized aripiprazole lauroxil in which particles of the aripiprazole lauroxil have a surface area of about 0.50 to about 3.3 m2/g; and crystals of aripiprazole lauroxil produced by such processes.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: April 13, 2021
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Wilfredo Morales, Tarek A. Zeidan, Renato A. Chiarella, Steven G. Wright, Jason M. Perry
  • Pharmaceutical Compositions Having Improved Storage Stability
    Publication number: 20200268891
    Abstract: The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent
    Type: Application
    Filed: March 30, 2020
    Publication date: August 27, 2020
    Inventors: Jason M. Perry, Daniel R. Deaver, Magali B. Hickey, Julius F. Remenar, Jennifer Vandiver, Michael J. Palmieri, JR., Zhengzheng Pan
  • Pharmaceutical compositions having improved storage stability
    Patent number: 10639376
    Abstract: The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: May 5, 2020
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Jason M. Perry, Daniel R. Deaver, Magali B. Hickey, Julius F. Remenar, Jennifer Vandiver, Michael J. Palmieri, Jr., Zhengzheng Pan
  • ANTIFUNGAL DRY POWDERS
    Publication number: 20200129428
    Abstract: The invention relates to dry powder formulations comprising respirable dry particles that contain 1) an antifungal agent in crystalline particulate form, 2) a stabilizer, and 3) one or more excipients.
    Type: Application
    Filed: October 13, 2017
    Publication date: April 30, 2020
    Inventors: Jason M. PERRY, Jean C. SUNG, David L. HAVA, Robert Clifford SAUNDERS, Hillary S. BERGSON, Andrew Emmet O'CONNOR
  • CRYSTALLIZATION PROCESS OF ARIPIPRAZOLE DERIVATIVES IN EXTENDED RELEASE FORMULATIONS FOR TREATMENT OF SCHIZOPHRENIA
    Publication number: 20200108063
    Abstract: Processes for providing depot injections of recrystallized aripiprazole lauroxil in which particles of the aripiprazole lauroxil have a surface area of about 0.50 to about 3.3 m2/g; and crystals of aripiprazole lauroxil produced by such processes.
    Type: Application
    Filed: October 8, 2019
    Publication date: April 9, 2020
    Inventors: Wilfredo Morales, Tarek A. Zeidan, Renato A. Chiarella, Steven G. Wright, Jason M. Perry
  • Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
    Patent number: 10478434
    Abstract: Processes for providing depot injections of recrystallized aripiprazole lauroxil in which particles of the aripiprazole lauroxil have a surface area of about 0.50 to about 3.3 m2/g; and crystals of aripiprazole lauroxil produced by such processes.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: November 19, 2019
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Wilfredo Morales, Tarek A. Zeidan, Renato A. Chiarella, Steven G. Wright, Jason M. Perry
  • Pharmaceutical Compositions Having Improved Storage Stability
    Publication number: 20190275155
    Abstract: The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent
    Type: Application
    Filed: May 29, 2019
    Publication date: September 12, 2019
    Inventors: Jason M. Perry, Daniel R. Deaver, Magali B. Hickey, Julius F. Remenar, Jennifer Vandiver, Michael J. Palmieri, JR., Zhengzheng Pan
  • Pharmaceutical Compositions Comprising Sorbitan Esters
    Publication number: 20190216805
    Abstract: The present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs.
    Type: Application
    Filed: January 15, 2019
    Publication date: July 18, 2019
    Inventors: Jason M. Perry, Daniel R. Deaver, Magali B. Hickey, Julius F. Remenar, Jennifer Vandiver